ERBB2 and breast cancer: Additionally, two phase 2 studies, IRIS (NCT04383275) and IRIS-C/D (NCT04383275), evaluate an oral chemotherapy regimen with either capecitabine or vinorelbine or endocrine therapy alone in combination with trastuzumab for lower-risk HER2-positive breast cancer.